Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5616820 | 0.82 | LMNA (0.43) | RAB9ANPC1SMN1; SMN2TDP1MAPT | |
| SCHEMBL28594804 | 0.81 | ALDH1A1 (0.49) | RAB9ANPC1SMN1; SMN2CA1CA2 | |
| SCHEMBL23662414 | 0.81 | LOXL2 (0.45) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23883482 | 0.81 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2CA1CA2 | |
| SCHEMBL16057140 | 0.79 | TSHR (0.55) | RAB9ANPC1SMN1; SMN2CA1CA2 | |
| SCHEMBL13041369 | 0.78 | MLYCD (0.46) | SMN1; SMN2MAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL6973943 | 0.77 | PDK2 (0.44) | RAB9ANPC1SMN1; SMN2CA1CA2 | |
| SCHEMBL18759164 | 0.77 | CPT1B (0.44) | ALDH1A1TSHR | |
| Fluoride SCHEMBL28205240 | 0.77 | CA1 (0.76) | RAB9ANPC1CA1CA2TDP1 | |
| SCHEMBL15956007 | 0.77 | CA1 (0.53) | RAB9ANPC1SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018169818-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | WANG XIAODONG (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2018-09-13 | — | — | US | disclosed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2008156601-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | OPRM1, OPRL1, OPRK1 | RAB9A 1956/4885NPC1 2545/4885SMN1; SMN2 1973/4885 |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | OPRM1, SIGMAR1, OPRK1 | RAB9A 3280/4885NPC1 2182/4885SMN1; SMN2 2013/4885 |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | HSD11B1, HSD3B1, HSD17B1 | RAB9A 4529/4885NPC1 391/4885SMN1; SMN2 4324/4885 |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | RAB9A 1956/4885NPC1 2545/4885SMN1; SMN2 1973/4885 |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | RAB9A 1956/4885NPC1 2545/4885SMN1; SMN2 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.